drugset / Trial / NCT00283478

Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer

NCT00283478

Completed 20 enrolled Kentuckiana Cancer Institute
RandomizedParallel-groupOpen-labelTreatment

Summary

To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.

Timeline

Start
2004-05
Primary completion
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Iscar Quercus Unknown
Background Gemcitabine Small molecule